# Tolerance and Growth Outcomes in Children Diagnosed With Cow's Milk Protein Allergy and Prescribed an Extensively Hydrolyzed Casein Formula (Damira 2000©) in Spain

> **NCT06273371** · — · COMPLETED · sponsor: **Lactalis** · enrollment: 61 (actual)

## Conditions studied

- Cow's Milk Protein Allergy

## Interventions

- **OTHER:** Damira 2000 Infant formula

## Key facts

- **NCT ID:** NCT06273371
- **Lead sponsor:** Lactalis
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-12-12
- **Primary completion:** 2023-12-21
- **Final completion:** 2023-12-21
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2024-02-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06273371

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06273371, "Tolerance and Growth Outcomes in Children Diagnosed With Cow's Milk Protein Allergy and Prescribed an Extensively Hydrolyzed Casein Formula (Damira 2000©) in Spain". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06273371. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*